Wearable Cardioverter-Defibrillator Recommendations for Wearable Cardioverter-Defibrillator References that support the recommendations are summarized in Online Data Supplement 56. COR LOE Recommendations IIa B-NR In patients with an ICD and a history of SCA or sustained VA in whom removal of the ICD is required (as with infection), the wearable cardioverter-defibrillator is reasonable for the prevention of SCD.S11.2-1 S11.2-4 IIb B-NR In patients at an increased risk of SCD but who are not ineligible for an ICD, such as awaiting cardiac transplant, having an LVEF of 35% or less and are within 40 days from an MI, or have newly diagnosed NICM, revascularization within the past 90 days, myocarditis or secondary cardiomyopathy or a systemic infection, the wearable cardioverter-defibrillator may be Synopsis The wearable cardioverter-defibrillator is a vestlike de- vice worn under the clothing that continuously moni- tors the heart rhythm and automatically delivers an electric shock when VF or VT is detected. This device is intended to be worn continuously, 24 hours per day, except when the wearer is bathing or showering. The wearable cardioverter-defibrillator has been ap- proved in the United States by the US Food and Drug Administration for patients who are at risk for SCA and are not candidates for or refuse an implantable A science advisory from the AHA summarizes the data and recommendations for the use of the wearable cardioverter-defibrillator.S11.2-4 Effective- ness of the wearable cardioverter-defibrillator in recog- nition and defibrillation of VF has been demonstrated in a number of studies, although no RCTs support the use of the wearable cardioverter-defibrillator. Among 3569 patients who received the device for various reasons, for at least 1 day in the US manufacturer registry, there were 80 VT/VF events in 59 patients, with a frequency of 1.7% per patient-year. 